Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Oncorus, a start-up in Cambridge, Massachusetts, that is developing oncolytic virus therapies, has raised $79.5 million in series B financing. The firm’s lead drug candidate is an engineered herpes simplex virus that will be injected directly into tumors with the goal of killing them. The virus is also programmed to produce five proteins—including IL-12 and checkpoint inhibitors of CTLA-4 and PD-1—intended to activate the immune system to kill tumors throughout the body. Oncorus will use the money to begin clinical trials in early 2020.
This article has been sent to the following recipient: